[8] Approved-drug labeling as a reference point The FDA-approved label for mecasermin (native IGF-1) provides the closest regulated analog and lists recognized risks of IGF-1 exposure, including hypoglycemia (owing to IGF-1s insulin-like metabolic action), intracranial hypertension, tonsillar/adenoidal hypertrophy, and the requirement for caution regarding neoplasia
Research Linking Ozempic to Blindness Research continues to emerge regarding serious side effects of Ozempic and other GLP-1 receptor agonists: January 2026: Patients Who Experienced Vision Loss After Ozempic Can Make Their Case in Federal Court In December of 2025, the Joint Panel on Multidistrict Litigation chose to centralize lawsuits filed by people who took GLP-1 drugs and then were diagnosed with NAION
1), better promoted a superior mMASI reduction (48%) than TC alone and proved to prevent further relapsing [81, 112]
It is a moment of quiet desperation, but also a moment of profound potential
No probiotic has been conclusively shown to produce meaningful or sustained weight loss on its own
For example, some of the therapeutic benefits observed for ebselen could be associated with this activity as it also inhibits NADPH oxidase activity
